Bristol-Myers Squibb (BMY) has been drawing attention after its shares closed at $56.72, leaving investors weighing how ...

If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks ...

Cash management is critical for pharmaceutical companies: The ability to fund drug innovation can make the difference between ...

Bristol Myers Squibb (BMY) is undervalued and poised for growth, with strong dividends and robust financials. Read here for ...

Bristol Myers Squibb has a robust pipeline with plenty of active programs, and its outlook for the next decade remains strong ...

Fintel reports that on January 7, 2026, UBS upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Neutral to Buy.

Bristol-Myers Squibb Company is rated a Buy with solid rebound and robust free cash flow margins. Learn more about BMY stock here.

Gilead Sciences promoted Keeley Wettan to EVP, general counsel, legal and compliance. She will join the senior leadership ...

Fintel reports that on January 7, 2026, UBS upgraded their outlook for Bristol-Myers Squibb Company - Preferred Security (OTCPK:BMYMP) from Neutral to Buy. Analyst Price Forecast Suggests 25.45% ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or ...

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap ...